Integer Holdings Corporation (ITGR) stock plummeted 5.01% during Friday's trading session, as the medical device company faced macroeconomic headwinds and uncertainty surrounding tariffs that weighed on its fourth-quarter performance.
The company reported adjusted earnings per share of $1.43 for Q4 2024, missing analysts' estimates by 2.1%. While revenues grew 11.1% year-over-year to $449.5 million, slightly beating expectations, Integer's gross margin contracted by 110 basis points to 25.9%, raising concerns about profitability.
Oppenheimer downgraded its rating on Integer stock from "Outperform" to "Perform", citing uncertainty around potential tariff-induced structural dislocations and the stock reaching its price target. The firm stated it is "adopting a wait and see stance" on Integer, despite the company's exposure to high-growth MedTech segments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。